​
​

Inhibikase Therapeutics Ownership | Who Owns Inhibikase Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Inhibikase Therapeutics Ownership Summary

Inhibikase Therapeutics is owned by 0.05% institutional investors, and 99.95% retail investors. Timber Point Global Allocations Instl is the top mutual fund, with 0.15% of its assets in Inhibikase Therapeutics shares.

IKT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockInhibikase Therapeutics0.05%-99.95%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20231-94.12%13,802-99.69%-0.02%--100.00%1-50.00%
Mar 31, 202317-10.53%4,421,111206.88%1649.22%7-22.22%2-60.00%
Dec 31, 202219-13.64%1,440,673-52.69%53.92%980.00%525.00%
Sep 30, 20222210.00%3,045,355-9.10%126.84%5-50.00%4-
Jun 30, 202220-13.04%3,350,331-21.64%134.62%1025.00%4-33.33%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Timber Point Global Allocations Instl11.00K0.15%-
Fidelity Extended Market Index37.20K0.06%8.04K
Northern Trust Extended Eq Market Idx2.62K0.04%-
NT Ext Equity Mkt Idx Fd - L2.62K0.04%-
NT Ext Equity Mkt Idx Fd - NL2.19K0.03%-
Vanguard Institutional Extnd Mkt Idx Tr16.72K0.03%-
NT Ext Equity Mkt Idx Fd - DC - NL - T21.77K0.02%5.00
SSgA U.S. Extended Market Index Class I1.42K0.02%-
Fidelity Series Total Market Index8.58K0.01%5.34K
SSgA U.S. Total Market Index Strategy581.000.01%172.00

Recent Insider Transactions

DateNameRoleActivityValue
Oct 21, 2024Bellini Roberto-Buy$2.00M
Oct 21, 2024Kush Arvind-Buy$198.65K
Oct 21, 2024Munshi Amit-Buy$500.05K
Aug 16, 2022Werner Milton H. President and CEOBuy$4.00K
May 27, 2022Werner Milton H. President and CEOBuy$4.88K

Insider Transactions Trends

DateBuySell
2024 Q43-
2024 Q3--
2024 Q2--
2023 Q2--
2023 Q1--

IKT Ownership FAQ

Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics shareholders are primarily institutional investors at 0.05%, followed by 0% insiders and 0% retail investors. The average institutional ownership in Inhibikase Therapeutics's industry, Biotech Stocks , is 44.97%, which Inhibikase Therapeutics falls below.

Does Blackrock own Inhibikase Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Inhibikase Therapeutics.

Who is the top mutual fund holder of Inhibikase Therapeutics shares?

Timber Point Global Allocations Instl is the top mutual fund holder of Inhibikase Therapeutics shares, with 0.15% of its total shares outstanding invested in 11K Inhibikase Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools